UK Biobank
UK Biobank is a large-scale biomedical database and research resource containing genetic, lifestyle and health information from half a million UK participants. The database, which is regularly augmented with additional data, is globally accessible to approved researchers and scientists undertaking vital research into the most common and life-threatening diseases. UK Biobank’s research resource is a major contributor to the advancement of modern medicine and treatment and has enabled several scientific discoveries that improve human health. In this exclusive interview, we speak with Professor Sir Rory Collins FMedSci FRS, Principal Investigator and Chief Executive of UK Biobank, to hear about the achievements to date and the ambitious and unique potential of this exciting project.
To begin, please tell us how UK Biobank came to fruition.
Understanding the factors that influence the onset and trajectory of common life-threatening and disabling conditions presents a critical challenge to medical science. Prospective cohort studies allow the study of individuals over a period of time, and can assess the exposure of individuals to risk factors before the onset and treatment of disease. The UK Medical Research Council and Wellcome Trust decided that they would fund a large prospective cohort at the turn of the century, and after a lot of discussion about what might be done and how it might be done, I was asked in 2005 to deliver the project.
The Lancet kit UK Biobank are using in the COVID sero-prevalence study. Credit UK Biobank
As Principal Investigator and Chief Executive, what are the aims of UK Biobank and how do you envision these aims will be achieved?
The aims are to allow as many researchers globally as possible to apply their expertise and imagination to the de-identified data from the 500,000 altruistic volunteers in as many different ways as possible in order to generate as much knowledge as possible about the causes of many different conditions, with the ultimate aim being to discover ways to prevent and treat those conditions better.
Around 500,000 volunteers have enrolled in the project – what data are being collected from volunteers and how is all this information being used?
At the baseline assessment, all volunteers completed a wide range of measures to ascertain their sociodemographic background, family history and early life exposures, psychosocial and environmental histories, and they also completed in-depth measures of their physical, health and cognitive function. Extensive phenotypic and genotypic information is being collected, including further data obtained from questionnaires, physical measures, sample assays, accelerometry, multimodal imaging, genome-wide genotyping and follow-up assessments conducted over the course of the project for a wide range of health-related outcomes.
High technology blood sample processing. Credit UK Biobank.
What opportunities are available for researchers through UK Biobank?
Uniquely, all of the data (and, indeed, assays of samples) are available to all bona fide researchers (both academic and commercial) worldwide without preferential access for all types of health-related research that is in the public interest. Researchers who fund the enhancement of the resource (e.g., assays of samples) may be given up to a 9-month exclusive access period to use the data that they have generated before those data are made available to all other researchers.
UK Biobank has already led to a wealth of publications in prestigious scientific journals. What do you consider to be UK Biobank’s most important findings to date?
The 500,000 participants were only recruited between 2006 and 2010 and, given that a prospective cohort requires long-term follow-up of health outcomes, the most important findings from UK Biobank will really only emerge over the next 5 to 10 years. Having said that, one important ‘finding’ is that the large investment in UK Biobank made by the Medical Research Council and Wellcome Trust (and others) is already starting to produce dividends in terms of the amount of research that can be conducted rapidly and efficiently by making a very large and very deeply characterised dataset freely available to lots of researchers (as illustrated by the numbers of publications and, increasingly, by their scientific importance). This is a testament to the vision of the funders to invest for the long term and to the altruism of the 500,000 people who volunteered to contribute their information to the resource.
Credit UK Biobank.
The project is, of course, made possible by the individuals who have volunteered to take part. How are the key findings and implications for health communicated to the general public?
Participants are informed regularly about the progress of the study (and, particularly, about major initiatives), as well as being invited to participate in additional assessments (such as the ongoing project to image 100,000 of the participants which is now half-way completed). They are also encouraged to review detailed updates on UK Biobank’s website, which are also available to other members of the public. Individual researchers who generate findings based on UK Biobank also put out their own press releases, which are often picked up by the news media.
In the midst of the current pandemic, a better understanding of health and disease is at the forefront of scientific as well as political agendas. What can UK Biobank offer to the COVID-19 response?
The first thing that we did was to put in place much more frequent updates from health record systems on health outcomes occurring among participants, and extended it to access to primary care records for the first time under emergency legal arrangements specifically for COVID-related research, and fast-tracked approval to use the data for such research. Findings about COVID-19 based on these data are already starting to emerge which we hope will help in its control.
At the request of the Wellcome Trust and UK Government, we have recruited about 10,000 of the volunteers, and extended recruitment to a similar number of their children and grandchildren aged over 18 (in order to include people aged less than 50 years), into a study to track the prevalence of previous infection with SARS-CoV-2 (based on a laboratory test for antibodies) throughout the second half of 2020 in different groups within the UK (e.g., different parts of the country, and in people of different age, gender, ethnicity, and socioeconomic status). The results of that study are being made publicly available, as well as being provided to the Government to help guide policy.
The vast UK Biobank freezer in Stockport is so large that several double decker buses could fit in it. Credit UK Biobank.
To conclude, if we may, with some personal reflection, what lessons do you feel we may learn from the COVID-19 pandemic in terms of healthcare in the coming decades?
Let reliable evidence really drive the strategies for the prevention of adverse health outcomes, whether that is due to infectious diseases or chronic diseases (e.g., the pandemic, increasingly in the poorer countries of the world, of tobacco-related deaths and disability that is largely ignored by the media…partly because tobacco is not ‘new’ and partly because the problem is moving away from the richer countries).
W: https://www.ukbiobank.ac.uk/
Twitter: @uk_biobank
Reference
https://doi.org/10.33548/SCIENTIA585
Want to republish our articles?
We encourage all formats of sharing and republishing of our articles. Whether you want to host on your website, publication or blog, we welcome this. Find out more
Creative Commons Licence
(CC BY 4.0)
This work is licensed under a Creative Commons Attribution 4.0 International License. 
What does this mean?
Share: You can copy and redistribute the material in any medium or format
Adapt: You can change, and build upon the material for any purpose, even commercially.
Credit: You must give appropriate credit, provide a link to the license, and indicate if changes were made.
More articles you may like
Dr Rhett Martin | Governing Nature at the Edge of Collapse
For millions of men, ageing brings with it a set of frustrating and often disruptive urinary symptoms. These symptoms, caused by benign prostatic hyperplasia, or BPH, can affect sleep, confidence, and overall quality of life. Traditionally, treatment follows a familiar path. Patients begin with medications, often for years, and may eventually progress to surgery if symptoms worsen. Yet this pathway is not without its drawbacks. Medications can cause side effects, while surgery carries risks and recovery time. In recent years, a minimally invasive interventional radiology procedure called prostate artery embolisation, or PAE, has begun to challenge this traditional model. At the forefront of this shift is a collaborative research group, led by Dr. Nicholas Brown of the University of Queensland, whose series of P-EASY studies has explored whether PAE could transform how BPH is treated, particularly at earlier stages.
Assoc Prof. Nicholas Brown | Rethinking Prostate Care: A New Frontier in Treating Benign Prostatic Hyperplasia
For millions of men, ageing brings with it a set of frustrating and often disruptive urinary symptoms. These symptoms, caused by benign prostatic hyperplasia, or BPH, can affect sleep, confidence, and overall quality of life. Traditionally, treatment follows a familiar path. Patients begin with medications, often for years, and may eventually progress to surgery if symptoms worsen. Yet this pathway is not without its drawbacks. Medications can cause side effects, while surgery carries risks and recovery time. In recent years, a minimally invasive interventional radiology procedure called prostate artery embolisation, or PAE, has begun to challenge this traditional model. At the forefront of this shift is a collaborative research group, led by Dr. Nicholas Brown of the University of Queensland, whose series of P-EASY studies has explored whether PAE could transform how BPH is treated, particularly at earlier stages.
Jean Lycke | Addressing Unmet Medical Needs in Mucosal Disease: A Close-to-Market Innovation Approach
Recurrent Aphthous Stomatitis (RAS) is an oral condition characterized by one or several painful mucosal ulcers. RAS affects a large proportion of the population and has a point prevalence of approximately 2–3%, daily. The etiology remains unknown, and there is currently no curative treatment. Most patients experience recurring episodes over time, with each episode typically lasting up to a week. Here, we describe the development of a mucoadhesive patch which, when applied over a RAS ulcer, provides rapid pain relief. The patch is easy for patients to apply when symptoms begin and has the potential to be used as an over-the-counter product. The development of the Mucocort mucoadhesive patch is an example of a Close-to-Market innovation strategy that embraces simplicity within a complex healthcare system. By simplifying the product concept, the team has reduced the number of regulatory steps required before market approval. This MedTech/Pharma innovation model, known as the “4R” framework – Re-purposing, Re-formulation, Re-positioning, and Re-patenting – has guided the program from concept to commercialization. In addition to the biodegradable mucoadhesive patch developed for RAS ulcers, the team is extending the innovation concept to a mucoadhesive gel formulation for the prevention and treatment of chemotherapy-induced mucositis. This gel-based program is being commercialized separately through MucoShield.
The Translational Asian Agerelated Macular Degeneration Program Phase 2 (TAAP-2): Reimagining the Future of Vision Care
Age-related macular degeneration, often abbreviated as AMD, is one of the leading causes of vision loss among older adults worldwide. In Asia, where populations are ageing rapidly, its impact is particularly profound. For many, the disease quietly erodes central vision, making everyday activities such as reading, driving, and recognising faces increasingly difficult. Against this backdrop, the Translational Asian Age-related Macular Degeneration Programme, or TAAP for short, has emerged as a bold and ambitious effort to confront the disease headon. Now in its second phase, TAAP-2 represents a significant evolution in both scientific scope and clinical ambition.